| scholarly article | Q13442814 |
| P50 | author | Helmar Bornemann-Cimenti | Q59689791 |
| P2093 | author name string | Andreas Sandner-Kiesling | |
| Istvan S Szilagyi | |||
| Mischa Wejbora | |||
| P2860 | cites work | Opioids for the management of breakthrough (episodic) pain in cancer patients | Q24244700 |
| Morphine and alternative opioids in cancer pain: the EAPC recommendations | Q24648711 | ||
| Breakthrough pain in chronic non-cancer pain: fact, fiction, or abuse. | Q30400836 | ||
| Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). | Q32147934 | ||
| Breakthrough pain: definition, prevalence and characteristics | Q33435886 | ||
| Single-dose pharmacokinetics of fentanyl buccal soluble film | Q34204903 | ||
| Pharmacological profiles of fentanyl analogs at mu, delta and kappa opiate receptors | Q34244033 | ||
| Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate | Q48618437 | ||
| Breakthrough pain: characteristics and impact in patients with cancer pain. | Q51089873 | ||
| Absorption and Bioavailability of Oral Transmucosal Fentanyl Citrate | Q51708443 | ||
| Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. | Q53288431 | ||
| Episodic (Breakthrough) Pain Prevalence in a Population of Cancer Pain Patients. Comparison of Clinical Diagnoses With the QUDEI—Italian Questionnaire for Intense Episodic Pain | Q57758048 | ||
| Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice | Q74317837 | ||
| PecSys: in situ gelling system for optimised nasal drug delivery | Q83766460 | ||
| Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care | Q34539972 | ||
| Opioid pharmacology | Q34774657 | ||
| Oral transmucosal fentanyl citrate in the outpatient management of severe cancer pain crises: a retrospective case series | Q35752351 | ||
| Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain | Q35826726 | ||
| Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain | Q36609652 | ||
| The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. | Q37245357 | ||
| The role of fentanyl in cancer-related pain | Q37609153 | ||
| Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer | Q37701842 | ||
| Treatment of breakthrough pain with fentanyl buccal tablet in opioid-tolerant patients with chronic pain: appropriate patient selection and management | Q37774033 | ||
| Fentanyl Buccal Tablet for Breakthrough Cancer Pain: Why Titrate? | Q37784261 | ||
| The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing | Q37826856 | ||
| Intranasal fentanyl for pain control: current status with a focus on patient considerations | Q37875708 | ||
| Opioids for the management of breakthrough cancer pain in adults: a systematic review undertaken as part of an EPCRC opioid guidelines project | Q37895000 | ||
| Fentanyl for breakthrough pain: a systematic review | Q37907299 | ||
| Pharmacotherapy for breakthrough cancer pain | Q37974707 | ||
| Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study. | Q39256721 | ||
| Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain | Q39268873 | ||
| Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain. | Q39270863 | ||
| The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain | Q39271527 | ||
| Formulations of fentanyl for the management of pain | Q39293912 | ||
| A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial | Q39297854 | ||
| Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief | Q39324051 | ||
| Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. | Q39331443 | ||
| Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study | Q39333256 | ||
| Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study | Q39341434 | ||
| Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study | Q39372438 | ||
| Cancer breakthrough pain characteristics and responses to treatment at a VA medical center | Q39399542 | ||
| Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain | Q39415383 | ||
| Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study | Q39441138 | ||
| Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain | Q39444283 | ||
| Role of intranasal fentanyl in breakthrough pain management in cancer patients | Q39801041 | ||
| Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study | Q43284157 | ||
| Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet for breakthrough pain | Q43682711 | ||
| Emerging opioid abuse in terminal cancer patients taking oral transmucosal fentanyl citrate for breakthrough pain | Q44331352 | ||
| Self-treatment with oral transmucosal fentanyl citrate to prevent emergency room visits for pain crises: patient self-reports of efficacy and utility | Q44669972 | ||
| Fentanyl | Q46501833 | ||
| Dose proportionality and pharmacokinetics of fentanyl buccal soluble film in healthy subjects: a phase I, open-label, three-period, crossover study | Q48199095 | ||
| Rampant caries from oral transmucosal fentanyl citrate lozenge abuse | Q48274859 | ||
| An economic evaluation of short-acting opioids for treatment of breakthrough pain in patients with cancer | Q48279154 | ||
| P433 | issue | 16 | |
| P921 | main subject | fentanyl | Q407541 |
| P304 | page(s) | 271-277 | |
| P577 | publication date | 2013-04-19 | |
| P1433 | published in | Deutsches Ärzteblatt international | Q27722165 |
| P1476 | title | Fentanyl for the treatment of tumor-related breakthrough pain | |
| P478 | volume | 110 |
| Q33970064 | Breakthrough cancer pain (BTcP): a synthesis of taxonomy, pathogenesis, therapy, and good clinical practice in adult patients in Italy. |
| Q42965858 | Correspondence (letter to the editor): Lack of precision in colloquial language results in incorrect therapeutic recommendation |
| Q86063584 | Correspondence (reply): In reply |
| Q51741034 | The effect of nitrous oxide in comparison to oxygen combined with fentanyl on the hospitalization time and pain reduction in renal colic patients at emergency department. |
| Q86825057 | [Topical pain therapy in oral mucositis: a systematic review] |
Search more.